Biocartis Group NV (XBRU:BCART) Debt-to-Equity : -2.82 (As of Jun. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Biocartis Group NV Debt-to-Equity?

Biocartis Group NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €17.98 Mil. Biocartis Group NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €134.27 Mil. Biocartis Group NV's Total Stockholders Equity for the quarter that ended in Jun. 2023 was €-53.99 Mil. Biocartis Group NV's debt to equity for the quarter that ended in Jun. 2023 was -2.82.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Biocartis Group NV's Debt-to-Equity or its related term are showing as below:

XBRU:BCART' s Debt-to-Equity Range Over the Past 10 Years
Min: -658.2 Med: 0.32 Max: 4.09
Current: -2.82

During the past 11 years, the highest Debt-to-Equity Ratio of Biocartis Group NV was 4.09. The lowest was -658.20. And the median was 0.32.

XBRU:BCART's Debt-to-Equity is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 0.23 vs XBRU:BCART: -2.82

Biocartis Group NV Debt-to-Equity Historical Data

The historical data trend for Biocartis Group NV's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocartis Group NV Debt-to-Equity Chart

Biocartis Group NV Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

0.41

1.97

4.09

-4.55

-4.04

Biocartis Group NV Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Debt-to-Equity	Get a 7-Day Free Trial															-658.20	-4.55	-2.38	-4.04	-2.82

Competitive Comparison of Biocartis Group NV's Debt-to-Equity

For the Diagnostics & Research subindustry, Biocartis Group NV's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biocartis Group NV's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biocartis Group NV's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Biocartis Group NV's Debt-to-Equity falls into.

Biocartis Group NV Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Biocartis Group NV's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(20.597	+	101.758)	/	-30.284
	=	-4.04

Biocartis Group NV's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(17.982	+	134.265)	/	-53.987
	=	-2.82

Biocartis Group NV (XBRU:BCART) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Biocartis Group NV Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Biocartis Group NV's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocartis Group NV (XBRU:BCART) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biocartis Group NV (XBRU:BCART) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Generaal de Wittelaan 11 B, Mechelen, BEL, 2800

Website

https://www.biocartis.com

Biocartis Group NV is a commercial-stage molecular diagnostics company. It provides diagnostic solutions aimed at improving clinical practice for patients, clinicians, payers, and the industry. The firm has developed an MDx Idylla molecular diagnostic system for oncology and infectious disease segments. Its products include EGFR mutation assay, BRAF mutation test, NRAS mutation test, respiratory panel, etc. The firm derives the majority of its revenues from product sales.

Biocartis Group NV (XBRU:BCART) Headlines

No Headlines